Description
Efficacy and safety of ponatinib in CP-CML patients by number of prior TKIs: 4-year follow-up of the phase 2 PACE trial
€3.03
Efficacy and safety of ponatinib in CP-CML patients by number of prior TKIs: 4-year follow-up of the phase 2 PACE trial
You must be logged in to post a review.
Reviews
There are no reviews yet.